Logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
24 juil. 2023 09h00 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
Logo.png
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h45 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
Logo.png
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
27 juin 2023 08h45 HE | GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
Logo.png
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
13 juin 2023 08h35 HE | GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
Logo.jpg
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
31 mai 2023 09h15 HE | Biostage, Inc.
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs...
logo.png
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
22 mai 2023 08h45 HE | GRI Bio, Inc.
Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...
Logo.png
Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
04 mai 2023 16h30 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...
logo.png
Bioxytran Interview at the Emerging Growth Conference
01 mai 2023 08h00 HE | BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...
logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
27 avr. 2023 09h05 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or...
logo.png
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
24 avr. 2023 08h05 HE | GRI Bio, Inc.
LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...